The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.
Keywords: BPaL; Nix-TB; United States; antimicrobial resistance; bacteria; bedaquiline; drug monitoring; linezolid; pretomanid; tuberculosis and other mycobacteria.